ESMO 2024: ICI Rechallenge in Patients With Advanced RCC Does Not Improve Efficacy
Patients who progressed after one or two lines of therapy saw no survival benefit after repeat treatment with immune checkpoint inhibitors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.